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*An example of a Medication Therapy Management Service may be found at the end of this document.* 
 
Background 
As part of the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003, 
medication therapy management programs 
(MTMP) will be required for each sponsor of a 
private prescription drug plan (PDP) or Medicare 
Advantage Prescription Drug Plan (MA-PD).  
This is in addition to the requirements for 
formulary drugs, drug utilization, and quality 
assurance programs.  Each sponsor will contract 
with the government for these provisions as they 
relate to covered drugs.  The Medicare Voluntary 
Drug Benefit Program (Part D) will take effect on 
January 1, 2006.1 
This is the first time that Congress has 
recognized in national legislation the importance 
of pharmacist-provided drug therapy 
management.  It is also the first time that 
pharmacists will be allowed to bill for Medicare-
related patient care services.2  Optimizing the 
therapeutic outcome will be the goal.  Reports of 
outcomes will be required and reported nationally 
through prescription drug plan provider activities.   
Pharmacists are the only healthcare 
professionals specifically named in the Act to 
provide these services.  Programs must be 
developed with licensed practicing pharmacists 
and physicians.  Patients eligible for these services 
must have multiple chronic, high drug-cost 
conditions such as congestive heart failure, 
diabetes, and chronic obstructive pulmonary 
disease and be receiving multiple medications. It 
is likely that patients with annual drug costs 
exceeding a certain Centers for Medicare and 
Medicaid Services (CMS)-defined limit will be 
enrolled as targeted plan participants.2 
MTMP fees have not yet been defined, 
however certain provisions have been outlined.  
Part D enrollees will not be required to pay a 
separate fee for these services but the cost could 
be reflected in their premium rate.  In establishing 
MTMP service fees, plan sponsors must account 
for program implementation resources and time.  
CMS states that these fees will be separate and 
distinct from prescription fees.  No lower limit of 
pharmacist payment by plan sponsors has been set 
by CMS.   
Regulations will be written by CMS which will 
interpret and implement Congresses’ legislative 
intent.  These pending regulations will define 
pharmacists’ activity in MTMP.  Pharmacists and 
pharmacy organizations are being asked by CMS 
for advocacy recommendations in defining these 
activities.  It is extremely important for 
pharmacists to share the “success stories” of their 
well documented, cost-effective, and health-
saving MTMP’s.   
 
MTMP Success Stories 
There are numerous examples of studies and 
programs documenting the dramatic health 
improvement and healthcare expense reduction of 
pharmacist-managed therapies in a variety of 
settings.3 
The Asheville Project is a classic example of a 
community pharmacist-managed diabetic care 
program.  Community pharmacists provided 
diabetes education, blood glucose meter training, 
clinical assessment, and patient monitoring that 
resulted in improvements of HgA1c and lipid 
levels for participating patients. The total average 
direct medical costs decreased by $1,200 to 
$1,872 per patient per year.  Patients experienced 
a reduction in sick time for one employer group, 
with estimated increases in productivity at 
$18,000 annually.4 
Pharmaceutical care services to Medicaid 
patients in Mississippi were recognized in 1998.  
Disease state certified pharmacists providing 
diabetes, asthma, hyperlipidemia, and coagulation 
services under physician approved protocols 
received reimbursement for their services.5   
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Ambulatory clinical pharmacy services 
provided by Harborview Medical Center in 
Seattle, Washington have demonstrated 
significant contributions through their programs.  
Their hypertension management project in 1995 
provided cost savings of $192 per patient per year 
related to reduced drug costs.  Patients had 
improved blood pressure control and there was 
high patient and provider satisfaction.6  
 
Scope of MTMP Services 
Besides services to patients with congestive 
heart failure, diabetes, and chronic obstructive 
pulmonary disease as mentioned in the Act, other 
services could include: 
• Performance of patient health status 
assessment 
• Devising prescription treatment plans 
• Managing high cost “specialty” medications 
• Evaluating and monitoring patient response to 
drug therapy 
• Providing patient and caregiver education 
• Coordinating therapy with other care 
management services 
• Participation in state-approved collaborative 
drug therapy management 
• Providing patient compliance programs 
• Detection and prevention programs for 
adverse drug events 
• Monitoring and prevention of over-and-under 
utilization of medications 
 
MTMP Endorsing Organizations 
MTMP as an essential part of the Medicare 
Part D prescription drug plan is endorsed by the 
following pharmacy organizations: Academy of 
Managed Care Pharmacy, American Association 
of Colleges of Pharmacy, American College of 
Apothecaries, American College of Clinical 
Pharmacy, American Pharmacists Association, 
American Society of Consultant Pharmacists, 
American Society of Health-System Pharmacists, 
National Association of Boards of Pharmacy, 
National Association of Chain Drug Stores, 
National Community Pharmacists Association, 
and the National Council of State Association 
Executives.  These organizations participated in 
the development of the MTMP definition sent to 
CMS and responded to CMS questions regarding 
MTMP. 
 
Remaining Questions 
Pharmacists, pharmaceutical organizations, 
and CMS itself have numerous questions yet to be 
answered.  Some commonly shared questions 
follow: 
• What minimum standards will be 
established for defining multiple chronic 
diseases?  These should be set by CMS for 
national application and not left to plan 
sponsors. 
• What level of annual Part D drug cost will 
be established for Medicare patients to 
qualify for MTMP? 
• What universal components should be 
included in MTMP services? 
• What are MTMP best practices?  
Examples might include: communication 
type and patient-physician-pharmacist 
collaborative therapeutic goal setting. 
• What minimum pharmacist qualifications 
will be established?  Presently, CMS states 
a licensed practicing pharmacist is 
qualified.   
• Who should the service provider be?  CMS 
believes that the individual patient’s need 
in the patient’s healthcare setting is the 
determining factor.  That is, a patient in a 
long-term care facility would be served by 
the facility consultant pharmacist.  
Ambulatory patients would be served by 
their community pharmacist.  Hospitalized 
patients would be served by their hospital 
pharmacist.  Other health professionals, 
such as nurses, may be allowed to provide 
services depending on the patient needs 
and the professional scope of practice. 
 
Conclusion 
Though there are numerous questions to be 
answered, this is a very exciting time for 
pharmacists in the U.S.  With this new legislation, 
pharmacists will be even more actively involved 
in providing pharmaceutical care services to 
patients.  It is essential that pharmacists are active 
advocates providing guidance to professional 
organization and government leaders during these 
times of plan formation.  Pharmacists are 
encouraged to communicate with their 
professional organizations and to visit the CMS 
website for updated information at: 
http://www.cms.hhs.gov/regulations/. 
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Community Care Rx Working with Outcomes Pharmaceutical 
 Health Care to Provide Medication Therapy Management Services 
 
 
The following excerpts are reprinted with 
permission from Community Care Rx concerning their 
medication therapy management services.  October 27, 
2004. 
 
Community Care Rx (CCRX) announces a new 
agreement with Outcomes Pharmaceutical Health 
Care (Outcomes) to provide Medication Therapy 
Management Services (MTMS) through 
participating pharmacies.  These services will be 
funded with monies originally set aside to pay 
pharmacists for their education and outreach 
efforts connected with enrolling Medicare 
beneficiaries into the Community Care Rx 
Medicare-approved drug discount card program. 
Medication Therapy Management Services 
utilize pharmacists and/or other health care 
professionals to proactively manage the cost and 
effectiveness of pharmaceuticals.  The services 
were promulgated by the 2003 Medicare 
Modernization Act and are mandated to begin by 
2006.  Community Care Rx is the first Medicare-
approved drug discount card to bring such a 
program to market.  
“Our agreement with Outcomes 
Pharmaceutical Health Care marks the 
achievement of yet another goal for the 
Community Care Rx Program,” said Bruce 
Roberts, R.Ph., chairman of the CCRx board and 
NCPA executive vice president and CEO.  “Our 
goal has been to create a benefit that will fully 
utilize the expertise of the pharmacist in order to 
bring about optimal patient outcomes and, 
ultimately, save health care dollars.  Through our 
agreement with Outcomes, we will pay 
pharmacists for their expert counsel and will 
demonstrate to CMS and other payors the value of 
pharmacist care.” 
Through the program, covered seniors will 
have access to specially trained “Outcomes 
Personal Pharmacists” in their area to help them 
navigate the least expensive, most clinically 
appropriate medications to treat their specific 
conditions.  Thousands of community pharmacists 
across the country have earned the Outcomes 
Personal Pharmacist designation with many more 
expected to do so in the coming months.  Training 
can be completed by going to: 
www.getoutcomes.com. 
This new alliance will enhance communication 
between Community Care Rx beneficiaries and 
their pharmacists and will provide the Centers for 
Medicare and Medicaid Services (CMS) a 
demonstration of an MTMS best practice model 
for the 2006 Medicare Part D benefit. 
Outcomes Pharmaceutical Health Care is the 
market leader in medication therapy management 
services.  The Des Moines, Iowa based firm has a 
five year track record in administering such 
services to employer groups, health plans, and 
government sponsored programs.  For more 
information, visit www.getoutcomes.com. 
Community Care Rx, a collaboration between 
Computer Sciences Corporation (CSC), 
MemberHealth, Inc. (MH), the National 
Community Pharmacists Association (NCPA) and 
the Senior Care Pharmacy Alliance (SCPA), has 
approximately 50,000 pharmacies in its 
nationwide network.  More than 70 state and 
industry organizations, representing more than 
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25,000 pharmacies, have endorsed Community 
Care Rx.  For more information, visit 
www.communitycarerx.com or www.ncpanet.org. 
NCPA represents the nation’s community 
pharmacists, a $78 billion marketplace, dispensing 
nearly half of the nation’s retail prescription 
medicines. For more information, visit 
www.ncpanet.org. 
 
 
 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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